256 related articles for article (PubMed ID: 30405089)
1. Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.
Zhang J; Zhang P; Zou Q; Li X; Fu J; Luo Y; Liang X; Jin Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30405089
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Dong S; Guo Y; Duan Y; Li Z; Wang C; Niu L; Wang N; Ma M; Shi Y; Zhang M
Anticancer Drugs; 2018 Aug; 29(7):637-645. PubMed ID: 29846247
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
4. Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma.
Li X; Qin F; Yang L; Mo L; Li L; Hou L
Int J Nanomedicine; 2014; 9():3971-85. PubMed ID: 25170267
[TBL] [Abstract][Full Text] [Related]
5. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
6. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
7. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
8. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
9. pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.
Dalela M; Shrivastav TG; Kharbanda S; Singh H
ACS Appl Mater Interfaces; 2015 Dec; 7(48):26530-48. PubMed ID: 26528585
[TBL] [Abstract][Full Text] [Related]
10. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
[TBL] [Abstract][Full Text] [Related]
11. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
[TBL] [Abstract][Full Text] [Related]
12. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.
Jian Y; Zhao M; Cao J; Fan T; Bu W; Yang Y; Li W; Zhang W; Qiao Y; Wang J; Wen A
Drug Des Devel Ther; 2020; 14():2355-2370. PubMed ID: 32606603
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
14. l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells.
Niu S; Bremner DH; Wu J; Wu J; Wang H; Li H; Qian Q; Zheng H; Zhu L
Drug Deliv; 2018 Nov; 25(1):1275-1288. PubMed ID: 29847177
[TBL] [Abstract][Full Text] [Related]
15. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
[TBL] [Abstract][Full Text] [Related]
16. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
Battogtokh G; Kang JH; Ko YT
Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer.
Sharma R; Yadav V; Jha S; Dighe S; Jain S
Carbohydr Polym; 2024 Aug; 338():122196. PubMed ID: 38763723
[TBL] [Abstract][Full Text] [Related]
18. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
19. Folic Acid and Poly(ethylene glycol) Decorated Paclitaxel Nanocrystals Exhibit Enhanced Stability and Breast Cancer-Targeting Capability.
Zhao J; Du J; Wang J; An N; Zhou K; Hu X; Dong Z; Liu Y
ACS Appl Mater Interfaces; 2021 Mar; 13(12):14577-14586. PubMed ID: 33728919
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation.
Madani F; Esnaashari SS; Bergonzi MC; Webster TJ; Younes HM; Khosravani M; Adabi M
Life Sci; 2020 Sep; 256():117943. PubMed ID: 32531377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]